{"id":"W1980282196","doi":"10.1016/j.biologicals.2014.05.005","title":"The challenge of indication extrapolation for infliximab biosimilars","year":2014,"lang":"en","type":"review","venue":"Biologicals","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":148,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; University of British Columbia; University of Toronto; University of Calgary; University of Alberta; Robarts Clinical Trials; Université de Montréal","funders":"Genentech; Celltrion; UCB; LEO Pharma; Ironwood Pharmaceuticals, Incorporated; Teva Pharmaceutical Industries; Gilead Sciences; ActoGeniX; Sanofi; Celgene; Biogen; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biosimilar; Infliximab; Medicine; Extrapolation; Pharmacology; Internal medicine; Mathematics; Tumor necrosis factor alpha; Statistics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001746658,0.0003213281,0.001448067,0.00008839345,0.0002112314,0.00001369504,0.000533536,0.001492889,0.0001215111],"category_scores_gemma":[0.001077321,0.0001471799,0.0006993801,0.0001698857,0.0005444093,0.00001607951,0.00009476535,0.0003179532,0.00003960123],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000271287,"about_ca_system_score_gemma":0.00005788348,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":7.240483e-7,"about_ca_topic_score_gemma":0.000001142045,"domain_scores_codex":[0.9973971,0.0008431506,0.0009626529,0.0004216763,0.00003289187,0.0003425332],"domain_scores_gemma":[0.9954501,0.003076104,0.0008953501,0.0004607074,0.00009509241,0.00002260678],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002320538,0.00005478681,0.000001663937,0.001104655,0.0002285342,5.578702e-8,0.000004619934,1.091824e-8,0.00008380033,0.008323904,0.001966124,0.9882087],"study_design_scores_gemma":[0.0001947267,0.0003956761,0.00001172246,0.0006938431,0.000405814,0.000003296011,0.000003747744,0.00000114435,0.0001125452,0.002466397,0.9955156,0.0001954554],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000001292243,0.9961721,0.0008837747,0.0005294189,0.0004332872,0.001134565,0.0001831884,0.00003557371,0.0006267602],"genre_scores_gemma":[0.0001199725,0.9983253,0.0005366821,0.00009434199,0.00009106662,0.0002471995,0.0002372153,0.00001656682,0.0003316743],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9935495,"threshold_uncertainty_score":0.9998034,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1216315824002214,"score_gpt":0.4075227525799325,"score_spread":0.2858911701797111,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}